Suppr超能文献

个性化糖尿病管理指南:专家的黄昏还是黎明?

Personalizing guidelines for diabetes management: twilight or dawn of the expert?

机构信息

Department of Diabetes, St Bartholomew's Hospital, London, EC1A 7BE, UK.

出版信息

BMC Med. 2013 Jul 10;11:161. doi: 10.1186/1741-7015-11-161.

Abstract

BACKGROUND

This opinion article on the management of type 2 diabetes considers the old and new format of guidelines and critical changes in the character of such guidelines. We highlight limitations of the guidelines and make recommendations for how treatment can be more personalised.

DISCUSSION

Published guidelines for the management of adult-onset non-insulin requiring diabetes have adopted a formulaic approach to patient management that can be overseen centrally and delivered by personnel with limited training. Recently, guidelines have taken a patient-centered, multiple risk-factor approach. Importantly, local funding issues are considered, but drive the final action and not the decision-making process. The nature of the disease can be determined by laboratory tests, including screening for diabetes-associated autoantibodies. The strategy remains step-up, with intensification of drug or insulin dose. As with past guidelines, there is an assumption that in each patient with type 2 diabetes, metformin is used initially, but targets and therapies then veer in different directions to create a matrix of options based on the features and responses of each individual. Factors to consider include: (A)ge, (B)ody weight, (C)omplications and co-morbidities, Diabetes (D)uration and (E)xpense, but also patient preference and patient response.

SUMMARY

Guidelines for the management of type 2 diabetes have important limitations and a patient-centered, multiple target, multiple therapy approach is proposed.

摘要

背景

本文是一篇关于 2 型糖尿病管理的观点文章,探讨了新旧指南格式以及此类指南性质的重大变化。我们强调了指南的局限性,并就如何使治疗更具个性化提出了建议。

讨论

成人发病的非胰岛素依赖型糖尿病管理指南采用了一种针对患者管理的公式化方法,可以由经过有限培训的人员进行集中监督和实施。最近,指南采取了以患者为中心、多危险因素的方法。重要的是,要考虑当地的资金问题,但这些问题是决定最终行动,而不是决策过程的因素。疾病的性质可以通过实验室检查来确定,包括筛查与糖尿病相关的自身抗体。策略仍然是逐步升级,即增加药物或胰岛素剂量。与以往的指南一样,假设在每个 2 型糖尿病患者中,最初使用二甲双胍,但随后根据每个患者的特征和反应,针对目标和治疗方法会出现分歧,从而产生一系列的选择方案。需要考虑的因素包括:(A)年龄、(B)体重、(C)并发症和合并症、(D)糖尿病病程和(E)费用,但也需要考虑患者的偏好和患者的反应。

总结

2 型糖尿病管理指南存在重要的局限性,我们提出了一种以患者为中心、多目标、多疗法的方法。

相似文献

1
Personalizing guidelines for diabetes management: twilight or dawn of the expert?
BMC Med. 2013 Jul 10;11:161. doi: 10.1186/1741-7015-11-161.
2
Person-centred type 2 diabetes care: time for a paradigm shift.
Lancet Diabetes Endocrinol. 2018 Apr;6(4):264-266. doi: 10.1016/S2213-8587(17)30193-6. Epub 2017 Jun 9.
3
NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.
Diabet Med. 2015 Nov;32(11):1398-403. doi: 10.1111/dme.12952. Epub 2015 Sep 23.
4
Current management of diabetes mellitus and future directions in care.
Postgrad Med J. 2015 Nov;91(1081):612-21. doi: 10.1136/postgradmedj-2014-133200. Epub 2015 Oct 9.
5
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
[Important epidemiological features of the treatment of type 2 diabetes].
Semergen. 2014 Jul;40 Suppl 2:1-8. doi: 10.1016/S1138-3593(14)74384-9.
7
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):311-321. doi: 10.1080/17425255.2017.1251579. Epub 2016 Nov 3.
8
Precision medicine in the management of type 2 diabetes.
Lancet Diabetes Endocrinol. 2018 Nov;6(11):891-900. doi: 10.1016/S2213-8587(18)30052-4. Epub 2018 Apr 23.
10
[Guidelines for the management of diabetes mellitus type 2].
Semergen. 2014 Sep;40 Suppl 4:11-8. doi: 10.1016/S1138-3593(14)74392-8.

引用本文的文献

1
Precision Health Care Elements, Definitions, and Strategies for Patients with Diabetes: A Literature Review.
Int J Environ Res Public Health. 2021 Jun 17;18(12):6535. doi: 10.3390/ijerph18126535.
2

本文引用的文献

1
Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7.
Diabetes Care. 2013 Apr;36(4):908-13. doi: 10.2337/dc12-0931. Epub 2012 Dec 17.
2
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
Lancet. 2013 Jan 12;381(9861):117-24. doi: 10.1016/S0140-6736(12)61267-7. Epub 2012 Nov 7.
3
Comparing diabetes drugs--helping clinical decisions?
Lancet. 2013 Jan 12;381(9861):93-4. doi: 10.1016/S0140-6736(12)61576-1. Epub 2012 Nov 7.
7
Gestational diabetes mellitus: risks and management during and after pregnancy.
Nat Rev Endocrinol. 2012 Nov;8(11):639-49. doi: 10.1038/nrendo.2012.96. Epub 2012 Jul 3.
8
Fenofibrate - a potential systemic treatment for diabetic retinopathy?
Am J Ophthalmol. 2012 Jul;154(1):6-12. doi: 10.1016/j.ajo.2012.03.013.
9
Basal insulin and cardiovascular and other outcomes in dysglycemia.
N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验